AbbVie Stock Slips As Humira Struggles Continue, But Drugmaker Raises OutlookInvestors Business Daily • 10/27/23
AbbVie results beat expectations despite low-cost competition to blockbuster HumiraMarket Watch • 10/27/23
Earnings Previews for AbbVie, Chevron, Exxon Mobil; All Reporting Friday Morning24/7 Wall Street • 10/25/23
Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar LinesPRNewsWire • 10/24/23
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001Business Wire • 10/23/23
My Dividend Stock Portfolio: New September Dividend Record - 98 Holdings With 22 BuysSeeking Alpha • 10/18/23
AbbVie: Why You Should Pay Attention To This High-Yielding Dividend King (Rating Downgrade)Seeking Alpha • 10/17/23